Cancer Advances, Inc. Announces Abstract and Poster Presentation at ASCO GI – Role of an anti-gastrin vaccine (PAS) in combination with a PD-1 antibody on growth and metastasis of gastric cancer

DURHAM, N.C., Jan. 19, 2022 (GLOBE NEWSWIRE) — Cancer Advances, Inc., a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal cancers, will host a virtual presentation of its poster at the American Society of Clinical Oncology’s...

Cancer Advances, Inc. Announces Publication, “Gastrin Vaccine Alone and in Combination with an Immune Checkpoint Antibody Inhibits Growth and Metastases of Gastric Cancer” in Frontiers in Oncology

DURHAM, N.C., Dec. 06, 2021 (GLOBE NEWSWIRE) — Cancer Advances, Inc., a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal cancers, announces a new publication in Frontiers in Oncology, section Gastrointestinal Cancers: Gastric...

November 11, 2019 – Cancer Advances, Inc. announces a new publication “Vaccine Against Gastrin, a Polyclonal Antibody Stimulator, Decreases Pancreatic Cancer Metastases” in the American Journal of Physiology—Gastrointestinal and Liver Physiology

• Immune competent female mice with pancreatic cancer treated with Polyclonal Antibody Stimulator (PAS) vaccine had significantly smaller tumors and fewer metastases than control mice. • PAS vaccine decreased metastasis by decreasing key pathway proteins involved in...